안질환 치료제 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 처방 유형별, 치료법별, 최종사용자별, 지역별 및 경쟁(2021-2031년)

The Global Optical Disorders Drugs Market is projected to experience substantial growth, expanding from USD 23.88 Billion in 2025 to USD 51.24 Billion by 2031, at a CAGR of 13.57%. This market encompasses pharmaceutical agents developed to treat various ocular pathologies, including glaucoma, age-related macular degeneration, and diabetic retinopathy, by mechanisms such as intraocular pressure regulation, angiogenesis inhibition, or inflammation reduction to preserve vision. The market's expansion is largely driven by a globally aging population and the increasing prevalence of chronic lifestyle diseases, like diabetes, which significantly raise the incidence of retinal conditions. Furthermore, improved diagnostic infrastructure in developing nations is progressively enhancing patient access to essential ophthalmic care. Despite this potential, the high cost of novel biologic therapies continues to impede market growth, often limiting access in lower-income regions. In 2025, an estimated 1.1 billion people worldwide lived with sight loss, highlighting a critical need for affordable therapeutic solutions, yet stringent reimbursement policies and insufficient healthcare funding challenge the broad adoption of premium ocular drugs.

Market Driver

The escalating global incidence of diabetic retinopathy and other lifestyle-related disorders serves as a primary driver for the optical disorders drugs market. Sedentary lifestyles contribute to metabolic conditions, leading to a significant increase in retinal complications requiring pharmacological intervention. For example, in 2020, approximately 1.07 million people globally were blind due to diabetic retinopathy, necessitating continuous anti-VEGF therapies to prevent irreversible vision loss. This growing patient pool underscores the immense commercial opportunity, as evidenced by the Eylea franchise's global net sales totaling $9.38 billion in 2023. Additionally, advancements in ocular drug delivery systems and novel ophthalmic biologics are further propelling market expansion. Innovation is shifting towards sustained-release technologies and bispecific antibodies, which extend treatment intervals and improve patient compliance compared to traditional monthly injections. This trend, exemplified by the $2.4 billion in sales for the bispecific antibody Vabysmo in 2023, enhances clinical outcomes and supports premium pricing strategies, thereby bolstering overall market revenue.

Market Challenge

The high cost of novel biologic therapies represents a significant obstacle to the commercial expansion of the Global Optical Disorders Drugs Market. Although these premium agents demonstrate clinical efficacy for conditions such as wet age-related macular degeneration and diabetic macular edema, their pricing structures frequently exceed the financial capacity of healthcare systems and individual payers. Consequently, strict reimbursement policies and limited funding availability compel healthcare providers to prioritize cost containment over clinical preference, thereby restricting the adoption of branded therapeutics. This financial pressure often leads physicians to opt for cheaper, off-label alternatives or delay necessary treatments, which directly diminishes the market share of approved, higher-priced drugs. The impact of these economic constraints is evident in industry data, with approximately 93% of surveyed retina specialists in 2025 reporting switches to lower-cost therapeutic alternatives due to unreliable copay assistance and funding shortages. Such shifts not only reduce revenue trajectories for manufacturers of proprietary biologic drugs but also underscore the market's susceptibility to pricing sensitivities, indicating that without sustainable reimbursement models, the growth potential of advanced ocular therapies will remain constrained by affordability barriers.

Market Trends

The commercialization of complement inhibitors for geographic atrophy (GA) marks a transformative shift in the market, establishing a new therapeutic segment for this previously untreatable advanced form of dry age-related macular degeneration. Unlike standard anti-VEGF agents that target angiogenesis in wet AMD, these novel therapeutics regulate the overactivation of the complement cascade to slow the expansion of retinal lesions. The rapid clinical uptake of these first-in-class C3 and C5 inhibitors highlights the urgent demand for treatments capable of preserving visual function in non-exudative conditions. The strong market entry is validated by Apellis Pharmaceuticals reporting U.S. net product revenue of $150.9 million for its GA therapy, Syfovre, in Q3 2025. Simultaneously, the expansion of gene therapy pipelines is advancing the development of one-time curative interventions for inherited retinal disorders and chronic vascular retinopathies. Pharmaceutical companies are increasingly utilizing adeno-associated virus (AAV) vectors to deliver functional genetic material directly to retinal cells, aiming for durable efficacy that overcomes the limitations of chronic monthly injections. This strategic focus involves substantial capital investment into late-stage clinical trials to establish genetic medicines as viable foundations for treating conditions like wet AMD and diabetic macular edema, as demonstrated by 4D Molecular Therapeutics' reported cash position of $417 million to fund accelerated Phase 3 development of its intravitreal genetic medicine, 4D-150, in Q2 2025.

Key Market Players

• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Pfizer Inc.
• Johnson & Johnson
• AbbVie Inc.
• Bayer AG
• Regeneron Pharmaceuticals, Inc.
• Alcon Inc.
• Bausch Health Companies Inc.
• Santen Pharmaceutical Co., Ltd.

Report Scope

In this report, the Global Optical Disorders Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Optical Disorders Drugs Market, By Prescription Type

• Over-The-Counter Drugs
• Prescription Ophthalmic Drugs

Optical Disorders Drugs Market, By Therapeutics

• Age-Related Macular Degeneration
• Conjunctivitis
• Diabetic Macular Edema
• Diabetic Retinopathy
• Dry Eye
• Eye Cancer
• Glaucoma
• Others

Optical Disorders Drugs Market, By End User

• Diagnostic Centers
• Eye Clinics
• Hospitals

Optical Disorders Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Optical Disorders Drugs Market.

Available Customizations:

Global Optical Disorders Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Optical Disorders Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Prescription Type (Over-The-Counter Drugs, Prescription Ophthalmic Drugs)
  • 5.2.2. By Therapeutics (Age-Related Macular Degeneration, Conjunctivitis, Diabetic Macular Edema, Diabetic Retinopathy, Dry Eye, Eye Cancer, Glaucoma, Others)
  • 5.2.3. By End User (Diagnostic Centers, Eye Clinics, Hospitals)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Optical Disorders Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Prescription Type
  • 6.2.2. By Therapeutics
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Optical Disorders Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Prescription Type
      • 6.3.1.2.2. By Therapeutics
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Optical Disorders Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Prescription Type
      • 6.3.2.2.2. By Therapeutics
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Optical Disorders Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Prescription Type
      • 6.3.3.2.2. By Therapeutics
      • 6.3.3.2.3. By End User

7. Europe Optical Disorders Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Prescription Type
  • 7.2.2. By Therapeutics
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Optical Disorders Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Prescription Type
      • 7.3.1.2.2. By Therapeutics
      • 7.3.1.2.3. By End User
  • 7.3.2. France Optical Disorders Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Prescription Type
      • 7.3.2.2.2. By Therapeutics
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Optical Disorders Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Prescription Type
      • 7.3.3.2.2. By Therapeutics
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Optical Disorders Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Prescription Type
      • 7.3.4.2.2. By Therapeutics
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Optical Disorders Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Prescription Type
      • 7.3.5.2.2. By Therapeutics
      • 7.3.5.2.3. By End User

8. Asia Pacific Optical Disorders Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Prescription Type
  • 8.2.2. By Therapeutics
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Optical Disorders Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Prescription Type
      • 8.3.1.2.2. By Therapeutics
      • 8.3.1.2.3. By End User
  • 8.3.2. India Optical Disorders Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Prescription Type
      • 8.3.2.2.2. By Therapeutics
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Optical Disorders Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Prescription Type
      • 8.3.3.2.2. By Therapeutics
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Optical Disorders Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Prescription Type
      • 8.3.4.2.2. By Therapeutics
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Optical Disorders Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Prescription Type
      • 8.3.5.2.2. By Therapeutics
      • 8.3.5.2.3. By End User

9. Middle East & Africa Optical Disorders Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Prescription Type
  • 9.2.2. By Therapeutics
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Optical Disorders Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Prescription Type
      • 9.3.1.2.2. By Therapeutics
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Optical Disorders Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Prescription Type
      • 9.3.2.2.2. By Therapeutics
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Optical Disorders Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Prescription Type
      • 9.3.3.2.2. By Therapeutics
      • 9.3.3.2.3. By End User

10. South America Optical Disorders Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Prescription Type
  • 10.2.2. By Therapeutics
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Optical Disorders Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Prescription Type
      • 10.3.1.2.2. By Therapeutics
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Optical Disorders Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Prescription Type
      • 10.3.2.2.2. By Therapeutics
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Optical Disorders Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Prescription Type
      • 10.3.3.2.2. By Therapeutics
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Optical Disorders Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. F. Hoffmann-La Roche Ltd.
• 15.3. Pfizer Inc.
• 15.4. Johnson & Johnson
• 15.5. AbbVie Inc.
• 15.6. Bayer AG
• 15.7. Regeneron Pharmaceuticals, Inc.
• 15.8. Alcon Inc.
• 15.9. Bausch Health Companies Inc.
• 15.10. Santen Pharmaceutical Co., Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer